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Changes of voltage-gated ion channels and ligand-gated receptor channels caused by
mutation or autoimmune attack are the cause of so-called channelopathies in the central
and peripheral nervous system. We present the pathophysiology of channelopathies of
the neuromuscular junction in terms of loss-of-function and gain-of-function principles.
Autoantibodies generally have reduced access to the central nervous system, but in some
cases this is enough to cause disease. A review is provided of recent ﬁndings implicating
autoantibodies against ligand-activated receptor channels and potassium channels in
psychiatric and neurological disorders, including schizophrenia and limbic encephalitis.
The emergence of channelopathy-related neuropsychiatric disorders has implications for
research and practice.
Keywords: NMDA receptor, AMPA receptor, GABA receptor, glycine receptor, acetylcholine receptor, Caspr2, Lgi1,
potassium channel
Autoimmune diseases are estimated to affect between 7 and 9%
of the general population (Cooper et al., 2009). They can show
a wide expression of phenotypes ranging from endocrine, mus-
culoskeletal to neurological, and neuropsychiatric syndromes.
A number of central nervous system (CNS) disorders, such as
limbic encephalitis, have been demonstrated to associate with spe-
ciﬁc serum autoantibodies. Antibodies that are directed against
voltage-activated ion channels and ligand-activated ion channel
neurotransmitter receptors can be expected to have an important
impact on functioning of neurons in a neural network, possibly
leading to serious mental disturbances. In this connection it is
relevant to bear in mind that neurotransmitter receptor block-
ers such as phencyclidine (angel dust), quinuclidyl benzilate, and
lysergic acid diethylamide (LSD), affecting NMDA, muscarinic
acetylcholine (ACh), and 5HT receptors, respectively, are all potent
hallucinogens. As far as the NMDA receptor (NMDAR) is con-
cerned the blockers phencyclidine, ketamine and the drug MK801
have been shown to cause cognitive defects in various rodent stud-
ies (Jones et al., 2011;Wiescholleck andManahan-Vaughan, 2013).
Blockers of muscarinic receptors, e.g., scopolamine and piren-
zepine, affect working memory of rats in maze tasks (Graef et al.,
2011). Blockers of nicotinic receptors, mecamylamine and various
synthetic drugs that are more or less speciﬁc blockers of α7 and
α4β2 receptors, impair the performance of rats in a radial arm
maze (Graef et al., 2011).
Receptors play an important role in functioning of the ner-
vous system. Their essential functions are also illustrated by the
high conservation of amino acid sequence, structure, and func-
tion of receptor gene families. Furthermore, several defects in
ion channels cause impairment of neural function in both the
peripheral and the CNS. Before we focus on recent developments
in autoimmune channelopathies as a cause of mental illness in
subgroups of patients, we startwith a brief summary of neuromus-
cular channelopathies. This ﬁeld of research has been exemplary
for the study of individual ion channels or receptor channels with
patch clamp electrophysiological methods and this information is
likely to translate into insights about CNS channelopathies. In the
neuromuscular system this approach has allowed for the identi-
ﬁcation of the pathophysiological mechanisms of many genetic
or autoimmune defects of ion channels (Lehmann-Horn and
Jurkat-Rott, 1999; Lorenzon and Beam, 2000; Striessnig et al.,
2004; Cannon, 2010). In this review we discuss the evidence that
autoantibodies in neuropsychiatric disorders cause predominantly
a loss rather than a changed pattern of channel activity, pos-
sibly associated with neuroinﬂammation and neurodegenerative
changes.
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LOSS-OF-FUNCTION AND GAIN-OF-FUNCTION CHANGES IN
NEUROMUSCULAR CHANNELOPATHIES
Mutations can cause loss-of-function (L-O-F) either because the
corresponding proteins are so much changed that they cannot
be properly processed and incorporated into the membrane, or
that they are dysfunctional in the case that they are incorporated.
Such diseases are usually autosomal recessive because the other
wild-type chromosome provides unaffected copies of the channel
protein that may be enough to take over all necessary activity from
the dysfunctional channels so that the overt disease phenotype is
not expressed. This is the case with the chloride channel (Pusch,
2002; Ryan and Ptacek, 2010), potassium channels (Shillito et al.,
1995; Irani et al., 2010), and ACh receptor (AChR) channels in
muscle (Engel et al., 1999; Faber et al., 2009).
Voltage-activated channels open and close, and are inactivated
and re-activated as a function of membrane voltage and time.
Mutations occurring in the voltage-sensing part of the chan-
nel subunit can thus severely disrupt their ﬁnely tuned behavior
(Cannon, 2010; Jurkat-Rott et al., 2010a). Autosomal dominant
mutations, for example in genes encoding sodium channels, may
induce the channel to inactivate too slowly after opening, leading
to persistent depolarization of the membrane (Jurkat-Rott and
Lehmann-Horn, 2004; Jurkat-Rott et al., 2010a,b). Such mutant
channels with abnormal functional behavior result from gain-
of-function mutations although the word “gain,” perhaps, might
wrongly suggest that a mutation has caused the function to
“improve.” On the contrary, action potential formation may be
completely disrupted regardless of the fact that properly function-
ing ion channels are still expressed by the wild-type gene. This
is the case with sodium channel diseases in muscle (Jurkat-Rott
et al., 2010a) and in the slow channel syndrome with mutations
of the AChR where the channels stay open too long (Oosterhuis
et al., 1987; Engel et al., 1996).
Table 1 gives a list of the diseases that are caused by channel
dysfunction in the neuromuscular junction. A number of general
features emerge from research into these diseases:
(1) All membrane channels of the neuromuscular system, includ-
ing the AChR channel, have been found to be affected in
humans, either by mutation or by autoantibody attack. Some
of these channelopathies are rare but others, notably myasthe-
nia gravis, occur more frequently, i.e., 20 per 100,000 (Phillips,
2003).
(2) Given the delicate pattern of ion channel opening and clos-
ing it comes as no surprise that inherited changes can lead to
aberrant function of the channel, which hampers the essen-
tial features of transient inactivation and rapid repolarization.
Such changes affect sodium channels and are often of the
autosomal dominant typewhich cause long-lastingdepolariza-
tion (Jurkat-Rott and Lehmann-Horn, 2004; Jurkat-Rott et al.,
2010a,b).
(3) In hereditary channelopathies in muscle the clinical symp-
toms such as myotonia and paralysis are not present all
the time but occur in attacks, whose frequency may vary
considerably between patients. Between the attacks the mus-
cle shows a virtually normal performance (Lehmann-Horn
and Jurkat-Rott, 1999). Apparently, the phenotype becomes
overt only under certain, well-deﬁned changes of environ-
ment (potassium and carbohydrate intake) or usage of the
muscle.
(4) Although the symptoms of these channelopathies can be
largely predicted from the abnormalities observed when these
mutations are expressed in single cell systems, uncertainties,
and puzzles remain. For instance, myotonia in hyperkalemic
periodic paralysis (sodium channel mutation) can have the
same pattern as myotonia in Thomsen type chloride chan-
nel mutations (Jurkat-Rott et al., 2010a) and for the diagnosis
occasionally a genetic analysis is required in order to dis-
criminate between the two diseases. A formidable puzzle has
been hypokalemic periodic paralysis where periodic attacks
of weakness are associated with low values of blood potas-
sium. Responsible mutations have been found in channels
with a completely different function including L-type calcium
channels (channels involved in depolarization-contraction
coupling in muscle), sodium channels (muscle action poten-
tial), and potassium channels (inward rectiﬁer). Nearly all
mutations in hypokalemic periodic paralysis are missense
mutations at arginine in the voltage sensor S4 transmembrane
domain. Each alpha subunit of an ion channel for sodium,
potassium, or calcium has six transmembrane segments S1–
6 of which S4 contains many positively charged amino acids
including arginine. This positive charge is forced to move by
the electrical ﬁeld of the depolarization and themoving charge
gives rise to a gating current which causes the channel to open.
Mutational substitutions of arginine support an alternative
pathway for ion conduction in the form of protons, the gating
pore current, and it has been put forward that this could be the
cause of the aberrant depolarization during attack of paraly-
sis (Cannon, 2010; Matthews and Hanna, 2010). However, the
detailed pathophysiology of this disease has not yet been fully
unraveled.
(5) Autoimmune attack usually results in a loss-of-function of the
ion channels that are involved (although the terminology of
L-O-F is usually reserved for changes caused by genetic muta-
tions). However, themechanism throughwhich this is brought
about can be different. One manner, which might seem obvi-
ous, is rare, namely that the autoantibody directly inhibits
functioning of the ion channel or blocking it directly. This
seems to be the case in acquired neuromyotonia and in some
forms of myasthenia gravis (Shillito et al., 1995). More com-
mon though, is antigenic modulation where membrane chan-
nels or receptors are cross-linked by the antibody, a process that
is followedby endocytosis of the channel-antibody complex. In
the common type of myasthenia gravis, autoantibody reaction
against AChRs also strongly involves activation of comple-
ment, leading to local destruction of membrane at the endplate
(Gomez et al., 2010; Vincent, 2010). As a result, the muscle
membrane regenerates quickly butnowwith a reducednumber
of AChRs leading to failing neuromuscular transmission. Sim-
ilarly, in the Lambert–Eaton myasthenic syndrome, antibodies
decrease the density of presynaptic Ca channels (Fukunaga
et al., 1983).
(6) As far as we are aware, there is one exception to the general
rule that autoantibodies against AChRs lead to L-O-F changes.
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In the acquired slow channel syndrome antibodies against the
epsilon subunit cause the AChR channel to close more slowly
which leads to increased inﬂow of (cytotoxic) calcium ions
(Wintzen et al., 1998).
(7) Autoantibodies can be transferred from mother to embryo by
placental transfer. Antibodies that cause myasthenia gravis in
the pregnant mother may also cause reversible muscle weak-
ness in neonates. Moreover, maternal anti-AChR antibodies
may impair skeletal muscle development and cause arthro-
gryposis multiplex congenita, in which babies are born with
multiple joint contractures andmuscleweakness. In such cases,
themother is frequently asymptomatic, becausematernal anti-
bodies to the gamma subunit of the muscle AChR exclusively
bind to the embryonic muscle (Riemersma et al., 1996). In the
adult type AChR receptor, the gamma subunit is replaced by
an epsilon subunit, thus making the adult muscle resistant to
such autoantibodies.
(8) Although ion channels may be affected at the pore-forming
subunits, it should be borne in mind that ion channels have
channel-associated proteins that are important for their func-
tion. Also these are susceptible to mutations and autoimmune
attack. For example,mutations in theAChR-associated protein
of the synapse (rapsyn) and themuscle speciﬁc kinase (MuSK)
lead to (recessive) myasthenic syndromes; antibodies against
MuSK cause myasthenia gravis (for review, see Gomez et al.,
2010).
CHANNELOPATHIES IN NEUROPSYCHIATRIC
DISORDERS
GENETIC INVOLVEMENT OF ALTERED ION CHANNEL FUNCTIONS IN
NEUROPSYCHIATRIC DISORDERS
Thepathophysiologyof neuropsychiatric disorders like schizophre-
nia is still poorly understood, although evidence strongly suggests
that hypofunction of dopamine receptor and NMDAR and dys-
function of potassium channels play central roles (Stephan et al.,
2006; Corti et al., 2011; Vukadinovic and Rosenzweig, 2012).
Strong evidence from genetic studies in large (pooled) cohorts has
furthermore indicated that certain common and rare genetic vari-
ants increase risk for neuropsychiatric disorders including genes
encoding components of ion channels. For example, a genome-
wide analysis identiﬁed risk loci with shared effects on ﬁve major
neuropsychiatric disorders; this study showed that speciﬁc single
nucleotide polymorphisms indicated variation in L-type calcium
channel gene activity of two subunits, CACNA1C and CACNB2
(Smoller et al., 2013).
Genetic studies have furthermore identiﬁed the genetic vari-
ants in genes encoding human leukocyte antigen (HLA) regions
[major histocompatibility complex (MHC) molecules] as being
associated with schizophrenia risk; which is one of themost robust
ﬁndings in psychiatric genetics to date. This, together with other
evidence implicating the HLA DRB1 locus as being associated
with risk for schizophrenia and autism, may support the notion
for a role for neuroinﬂammation and possibly autoimmunity in
neuropsychiatric disorders (Crespi and Thiselton, 2011). Associ-
ation with HLA antigens in schizophrenia had been noted before
and different authors had already speculated some 20 years ago
toward the existence of subgroups of schizophrenics who have
immunological abnormalities like antinuclear antibodies in lupus
erythematosus, known as neuropsychiatric lupus (Ganguli et al.,
1993).
BLOOD–BRAIN BARRIER AND ACCESS OF AUTOANTIBODIES
TO THE CNS
It is a common misconception that the blood–brain barrier
(BBB) is completely impermeable to antibodies. In fact, anti-
bodies cross to a limited extent the human BBB (Poduslo et al.,
1994). They arrive into the cerebrospinal ﬂuid (CSF) with a rate
of 0.018 mg/min and have a turnover of 0.0036/min (compa-
rable to the CSF turnover; four times per day; Poduslo et al.,
1994). This very dynamic equilibrium results in immunoglob-
ulin G (IgG) levels in the brain of around 1% of the plasma levels
and IgG composes 9.8% of the protein in the CSF (Cutler et al.,
1970; Poduslo et al., 1994). There is a large body of evidence that
pathogenic autoantibodies (e.g., in autoimmune channelopathies)
reach sites in the CNS and have immunopathogenic effects there
(Diamond et al., 2009). Such diseases include paraneoplastic neu-
rological syndromes (Honnorat andAntoine, 2007), neuromyelitis
optica (Lennon et al., 2004), stiff-person’s syndrome (Solimena
et al., 1988), epilepsy with glutamic acid decarboxylase (GAD)
antibodies (Solimena et al., 1988; Errichiello et al., 2009), nar-
colepsy (Cvetkovic-Lopes et al., 2010), dyslexia (Vincent et al.,
2002), Morvan’s syndrome, and limbic encephalitis (Irani et al.,
2010). Moreover, it has been demonstrated in patients with
Alzheimer’s disease and in corresponding AD animal models that
intravenous injection of antibodies directed against aggregated
amyloid beta efﬁciently reduce amyloid plaque load in the brain
(Panza et al., 2010). The mechanisms by which antibodies pass the
BBB under normal conditions are still incompletely understood.
The BBB becomes much more permeable following local inﬂam-
mation reactions, e.g., in multiple sclerosis (0.107 mg/min; Cutler
et al., 1970). Moreover, neuroinﬂammation may lead to local pro-
duction of antibodies by B-cells and or plasma cells in the brain
itself.
However, in spite of this dynamic turnover of antibodies
between the periphery and the brain, well-deﬁned autoantibod-
ies of peripheral diseases, such as the Lambert–Eaton myasthenic
syndrome and neuromyotonia, do not have central effects despite
the fact that calcium Cav2.1 (P/Q-type) channels and potassium
channel complex proteins are also present in the brain and thus
could be targeted by these antibodies. So in some cases, CNS
autoimmune channelopathies occur only when the integrity of
the BBB is disrupted and higher ﬂow of antibodies gets access
to the brain. From this point of view it might be argued that
Morvan’s syndrome and acquired neuromyotonia might harbor
the same disease pathophysiology (Tables 1 and 2) and the same
immunological pathogenesis, with the exception however, that in
the case ofMorvan’s syndrome there is a spectrumof disease inten-
sities with a breach in the integrity of the BBB. In line with this is
the ﬁnding that mice immunized with a peptide producing both
anti-DNA and anti-NMDARantibodies do not showbrain pathol-
ogy unless the integrity of the BBB is challenged (Diamond et al.,
2009). Because it is unlikely that the BBB is equally permeable
to antibodies or antibody-producing cells throughout the brain,
the “phenotype” of the antibody effect may well depend on the
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Table 2 | Ion channel targets of autoantibodies in the brain.
Targeted antigen Disease(s) Subunit/associated
protein
Reference
Potassium channel/VGKC-complex Limbic encephalitis, Morvan’s
syndrome, Schizophrenia
LG1 or Caspr2
LG1 or Caspr2
Irani et al. (2010, 2011), Lai et al. (2010)
Irani et al. (2011), Zandi et al. (2011),
Steiner et al. (2013)
NMDAR Encephalitis, Schizophrenia NR1 Dalmau et al. (2011), Zandi et al. (2011),
Steiner et al. (2013)
AMPAR Limbic encephalitis Vincent et al. (2011)
Glutamic acid decarboxylase Limbic encephalitis, Stiff person
syndrome
Vincent et al. (2011), Graus et al. (2010)
Muscarinic AChR Schizophrenia M1; M2 Borda et al. (2002, 2004)
Nicotinic AChR Schizophrenia α7 Chandley et al. (2009)
GABABR Limbic encephalitis Vincent et al. (2011)
Glycine-R Progressive encephalomyelopathy Hutchinson et al. (2008)
location where the antibody enters the brain and factors affecting
the integrity of the BBB with respect to the transport of anti-
bodies may show regional speciﬁcity. This might explain why the
same autoantibodymight have substantially different pathological
effects between different groups of patients. For instance, anti-
bodies against potassium channel complex proteins are involved
in limbic encephalitis, Morvan’s syndrome (Irani et al., 2010), or
schizophrenia (Zandi et al., 2011); after lipopolysaccharide treat-
ment, anti-NMDAR antibodies attack channels in hippocampal
neuronswhile the same antibodies after treatmentwith adrenaline,
also known to breach BBB integrity, damage channels in other
regions of the brain (for a review, see Diamond et al., 2009).
GAIN-OF-FUNCTION, LOSS-OF-FUNCTION, NEUROINFLAMMATION, OR
NEURODEGENERATION?
In view of what we know about autoimmune channelopathies in
the neuromuscular junction to date, it is reasonable to surmise that
most CNS autoimmune channelopathies are probably of the loss-
of-function type, as happens inmyasthenia gravis, Lambert–Eaton
mysthenic syndrome, and acquired neuromyotonia where there is
loss of activity or number of AChRs, P/Q-type calcium channels,
and potassium channels, respectively (Shillito et al., 1995; Lang
and Vincent, 2009; Gomez et al., 2010). In addition, it is possible
that there is also complement-induced destruction of membrane
around the antigen target as happens in myasthenia gravis. This
could start degeneration of the neurons (or potentially also glia,
astrocytes, or oligodendrocytes) carrying the antigen. Obviously
these are important questions to be dealt with eventually because
the success of immunosuppressive therapywill depend onwhether
the antibody-induced defect is reversible.
AUTOIMMUNE TARGETS IN THE BRAIN AND NEUROPSYCHIATRIC
DISORDERS
Table 2 gives a summary of the ion channel targets for autoanti-
bodies in the brain and different diseases that are related to them.
Recently, antibodies to neuronal cell surface antigens have been
identiﬁed in cases of autoimmune encephalitis that respond to
immunotherapy (Zandi et al., 2011). Over two-thirds of patients
with NMDAR antibody encephalitis, and some with potassium
channel antibody associated limbic encephalitis, havemarked psy-
chiatric symptoms, or have their initial presentation at psychiatric
services (Creten et al., 2011). The psychiatric symptoms are similar
to those seen in schizophrenia including delusions, hallucina-
tions, and catatonic movement disorder. These antibodies seem
to be responsible for the pathophysiology because they seem to
be absent in healthy individuals, and in the majority of patients
with other neurological diseases (Zandi et al., 2011; Steiner et al.,
2013). Recently, several case reports described patients with
NMDAR or potassium channel antibodies suffering exclusively
from neuropsychiatric disorders; and, interestingly, treatment
with immunosuppressive agents resulted in long lasting clinical
improvement in one of these patients (Zandi et al., 2011; Steiner
et al., 2013). Although in one study NMDA antibodies were not
detected in a group of 80 patients with schizophrenia (Masdeu
et al., 2012), another study did report an increase in the prevalence
of diverse NMDA antibodies in patients with initial diagnosis of
schizophrenia (Steiner et al., 2013).
Antibodies to muscarinic AChRs (mAChRs) have been identi-
ﬁed in a small proportion of a group of schizophrenic patients,
and these antibodies were shown to interact with cerebral frontal
cortex mAChR, where they react against the second extracellular
loop of the M1 andM2 regions (Borda et al., 2002, 2004). Surpris-
ingly, these antibodies had an agonistic, “G-O-F”-like effect on
mAChRs, i.e., causing an increase of the cyclic GMP production,
accumulation of inositol phosphate, and translocation of protein
kinase C (Borda et al., 2002, 2004). Another studywas able to iden-
tify antibody titers in 23% of a cohort of 21 schizophrenia patients
against the alpha7 subunit of the nicotinic AChR (Chandley et al.,
2009).
Systemic lupus erythematosus (SLE) is known to be associated
with neuropsychiatric manifestations in some cases (Diamond
et al., 2009). A subset of antibodies to double stranded DNA
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(dsDNA) in patients with SLE cross-reacts with subunits of the
NMDAR2a and NMDAR2b on neuronal cells and cause neuronal
death by “G-O-F” effect on these receptors leading to excitation-
toxicity and apoptosis (DeGiorgio et al., 2001; Omdal et al., 2005).
Higher serum and CSF anti-NR2 region antibody levels correlate
with depressive mood in SLE patients (Lapteva et al., 2006; Yoshio
et al., 2006). Similar examples come from obsessive-compulsive
disorders where antibodies directed against basal ganglia antigens
occur 20% in of the patients compared to 4% in the controls
(Nicholson et al., 2012).
Like in neuromuscular diseases, ion channel-associated pro-
teins in the CNS are vulnerable as targets for autoantibodies. The
potassium channel is a case in point. Whereas antibodies directed
against channel-associated proteins have been shown to immuno-
precipitate the solubilized channel in radioimmune assays, in
neuromyotonia and also in (limbic) encephalitis, the autoantibody
has been shown in diagnostic cell-based assays to be directed not
against the potassium channel alpha subunit, but against leucine-
rich glioma inactivated 1 (Lgi1) or contactin-associated protein-
like 2 (Caspr2) which both are channel-associated proteins (Lai
et al., 2010; Dalmau et al., 2011).
Autoimmunity in mental illness is not limited to ion channels.
Katzav et al. (2007) found that injection of intracerebroventricu-
lar anti-ribosomal P antibodies induced depression-like behavior
in mice. A further example of autoimmunity is that antibodies
targeting the folate receptor (FR) have been found in early onset
low-functioning autism, where these antibodies seem to appear at
the age of 4–6 months. FR autoantibodies block the folate bind-
ing site of the membrane-attached FR on the choroid epithelial
cells, thereby inhibiting the transport of folate into the CSF. In
line with a putatively causal relation, changes in FR antibody titer
correlated with behavioral incidents, and interestingly, a regimen
of oral folic acid supplements was able to reverse or substantially
improve the clinical phenotype in some patients, particularly in
children diagnosed before 3 years of age (Ramaekers et al., 2005,
2007; Frye et al., 2013).
It is important to keep in mind that mental illness could also
have neurodevelopmental origins. Although many neurodevelop-
mental disorders are thought to have a major genetic component,
other components, such as environmental impact and associ-
ated gene–environment interactions have also been proposed (van
Os et al., 2010). Interestingly, a role for maternal autoantibodies
has been reported in a few neurodevelopmental phenotypes, e.g.,
autism, speciﬁc language difﬁculties, and dyslexia (Warren et al.,
1990; Vincent et al., 2002, 2003; Dalton et al., 2003; Martin et al.,
2008).
Penetration of IgGs into the brain has been proposed to be
greater in neonatal rats than in adult rats (Fabian and Hulsebosch,
1989). Consequently it is possible that maternal antibodies might
have easier access to receptors in the fetus brain, activate differ-
ent pathways, or have other effector functions. In addition, the
NMDAR, and some other receptors as well, can exist in two forms,
embryonic and adult types (Monyer et al., 1994; Fukaya et al.,
2005). Thus it is possible that antibodies selective against embry-
onic forms of the channel subunit are present in an asymptomatic
mother and cause a direct effect on the fetal brain during preg-
nancy. This would be analogous to the situation in arthrogryposis
multiplex congenita as explained above for the fetal muscle.
In some cases the auto-antibody-induced damage during brain
development may never lead to clinical manifestations or might
induce neuropsychiatric manifestations later in life after a second
hit, e.g., an environmental trigger. If true this would complicate
the diagnosis and investigation of disease pathology of these cases.
All in all, as an increasing number of patients with neu-
ropsychiatric disorders with autoimmune antibodies are being
reported, it would be important to start large systematic stud-
ies of patients, as well as of offspring and other relatives, in
order to examine the occurrence of autoimmune-related pathol-
ogy such as anti-channel antibodies. In addition, the study of
pathogenic antibodies may also enable novel treatment options
(using immunosuppressants, plasmapheresis, etc.) for neuropsy-
chiatric disorders.
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